<DOC>
	<DOCNO>NCT01879462</DOCNO>
	<brief_summary>GSK2878175 site IV NS5B non-nucleoside inhibitor ( NNI ) develop treatment chronic HCV infection . This study represent first administration GSK2878175 human define safety , tolerability , pharmacokinetics ( PK ) follow single repeat dos GSK2878175 healthy subject . This Phase 1 , randomize , single-blind , placebo-controlled , dose escalation study determine safety , tolerability , PK profile GSK2878175 single ( Part 1 ) repeat dos ( Part 2 ) healthy subject . In addition study explore effect moderate ( 30 % ) fat meal single dose PK endpoints healthy subject .</brief_summary>
	<brief_title>A First Time Human Study Investigate Safety , Tolerability Pharmacokinetics Single &amp; Repeat Escalating Doses GSK2878175 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Capable give write informed consent , include compliance requirement restriction list consent form . The subject able understand comply protocol requirement , instruction protocolstated restriction likely complete study plan . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test ECGs . There evidence cardiac , pulmonary , hepatic , biliary , gastrointestinal , renal disorder , cancer within past 5 year ( except localize situ cancer skin ) . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion report outside normal reference range healthy volunteer may include Investigator considers find unlikely introduce additional risk subject interfere study procedure . Body weight &gt; 50 Kilograms ( kg ) ( 110 pound ) men &gt; 45kg ( 99pounds ) woman body mass index ( BMI ) 18.532 kg/meter^2 inclusive allow . Male female 18 55 year age inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy [ definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ] ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milli international unit [ MlU ] /milliliter [ mL ] estradiol &lt; 40 picogram [ pg ] /mL [ &lt; 147 picomoles /litre ] confirmatory ] .. Male subject female partner childbearing potential must agree use contraception method . This criterion must follow time first dose study medication follow visit.his criterion must follow time first dose study medication follow visit ( 7 14 day post last dose ) . Aspartate Amino Transferase ( AST ) , Alanine Amino Transferase ( ALT ) , alkaline phosphatase , bilirubin , creatinine less upper limit normal . TSH within normal reference range . At discretion principle investigator ( PI ) subPI , value may repeat . White blood cell count ( include neutrophil count ) , hemoglobin , platelet reticulocytes great low limit normal . At discretion PI subPI , value may repeat . The subject 's systolic blood pressure inside range 90140 millimeter mercury ( mmHg , ) diastolic blood pressure inside range 4590 mmHg . Heart rate inside range 50100 beat per minute ( bpm ) female subject 45100 bpm male subject . Subject mentally legally incapacitate . Family history prolong QT syndrome ( Torsade de Pointes ) sudden cardiac death ; firstdegree relative myocardial infarction premature age ( &lt; 45 year male relative ; &lt; 55 year female relative ) . History active diagnosis diabetes mellitus . History active diagnosis thyroid disease . History active diagnosis pulmonary disease asthma , emphysema , chronic obstructive pulmonary disease interstitial lung disease . History regular alcohol consumption within 6 month study define : Australian standard : An average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 10 g alcohol : 270mL full strength beer ( 4.8 % ) , 375mL mid strength beer ( 3.5 % ) ,470mL light beer ( 2.7 % ) , 250mL premix full strength spirit ( 5 % ) , 100mL wine ( 13.5 % ) 30mL spirit ( 40 % ) . Unwilling abstain alcohol 48 hour prior start dose collection final pharmacokinetic sample treatment period . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication . A positive Hepatitis C antibody A positive prestudy Hepatitis B surface antigen . A positive test HIV antibody History regular use tobacco nicotinecontaining product within 3 month screen visit indication tobacco use evidence positive urine cotinine test screening . A positive prestudy drug/alcohol screen . Unwilling refrain use illicit drug adhere protocolstated restriction participate study . Pregnant female determine positive urine serum human chorionic gonadotropin ( hCG ) test screen prior dosing . QT interval correct heart rate ( Fridericia 's ) &gt; 450 millisecond ( msec ) ; QTc &gt; 480 msec subject Bundle Branch Block . Holter monitoring show one following : Any symptomatic arrhythmia ( except isolate extra systole ) . Sustained cardiac arrhythmia ( atrial fibrillation flutter , Supraventricular tachycardia ( SVT ) ( &gt; 10 consecutive beat ) . Sinus tachycardia ( supraventricular tachycardia ) great 150 bpm Nonsustained sustained ventricular tachycardia ( define &gt; 3 consecutive ventricular ectopic beat ) . Any conduction abnormality ( include specific leave right complete bundle branch block , Atrioventicular ( AV ) block [ 2nd degree high awake subject ] , WolffParkinsonWhite ( WPW ) syndrome , preexcitation syndrome ) . Symptomatic sinus pause sinus pause &gt; 3 second unless patient straining , vomit , type hypervagal response . 300 supraventricular ectopic beat 24 hour . 250 ventricular ectopic beat 24 hour Ischemia , diagnose sequence ECG change include flat slop STsegment depression &gt; 0.1 millivolt ( mV ) , gradual onset offset last minimum period 1 minute . Each episode ischemia must separate minimum duration least 1 minute , ST segment return back baseline ( 1x1x1 rule ) . Unable use spirometry equipment correctly . Abnormal spirometry result : Volume exhale end first second force expiration ( FEV1 ) less 80 % predict value , FEV1/ Forced Vital Capacity : determination vital capacity maximally force expiratory effort ( FVC ) less 70 % Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Consumption red wine , seville orange , grapefruit grapefruit juice , pummelo , satsuma , ugli , tangerine , tangelo , exotic citrus fruit , grapefruit hybrid fruit juices 5 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>chronic hepatitis C ( CHC )</keyword>
	<keyword>Hepatitis C virus ( HCV )</keyword>
	<keyword>NS5B</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>GSK2878175</keyword>
	<keyword>safety</keyword>
	<keyword>FTIH</keyword>
	<keyword>healthy subject</keyword>
</DOC>